WO2012131463A3 - Controlled release pharmaceutical dosage forms - Google Patents

Controlled release pharmaceutical dosage forms Download PDF

Info

Publication number
WO2012131463A3
WO2012131463A3 PCT/IB2012/000595 IB2012000595W WO2012131463A3 WO 2012131463 A3 WO2012131463 A3 WO 2012131463A3 IB 2012000595 W IB2012000595 W IB 2012000595W WO 2012131463 A3 WO2012131463 A3 WO 2012131463A3
Authority
WO
WIPO (PCT)
Prior art keywords
dosage forms
controlled release
pharmaceutical dosage
release pharmaceutical
layer
Prior art date
Application number
PCT/IB2012/000595
Other languages
French (fr)
Other versions
WO2012131463A2 (en
Inventor
Haiyong Hugh Huang
Original Assignee
Purdue Pharma L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to RS20150515A priority Critical patent/RS54152B1/en
Priority to SI201230275T priority patent/SI2688556T1/en
Application filed by Purdue Pharma L.P. filed Critical Purdue Pharma L.P.
Priority to BR112013024585A priority patent/BR112013024585A8/en
Priority to DK12717468.8T priority patent/DK2688556T3/en
Priority to JP2014500486A priority patent/JP5964940B2/en
Priority to KR1020137027839A priority patent/KR101619579B1/en
Priority to CN201280020303.9A priority patent/CN103547259A/en
Priority to AU2012235878A priority patent/AU2012235878B2/en
Priority to US14/004,857 priority patent/US20140056979A1/en
Priority to EP20120717468 priority patent/EP2688556B1/en
Priority to PL12717468T priority patent/PL2688556T3/en
Priority to CA2831218A priority patent/CA2831218C/en
Priority to NZ616600A priority patent/NZ616600B2/en
Priority to MEP-2015-116A priority patent/ME02189B/en
Priority to MX2013010987A priority patent/MX350875B/en
Priority to ES12717468.8T priority patent/ES2544735T3/en
Publication of WO2012131463A2 publication Critical patent/WO2012131463A2/en
Publication of WO2012131463A3 publication Critical patent/WO2012131463A3/en
Priority to IL228441A priority patent/IL228441B/en
Priority to ZA2013/07862A priority patent/ZA201307862B/en
Priority to HRP20150835TT priority patent/HRP20150835T1/en
Priority to SM201500209T priority patent/SMT201500209B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Abstract

The present invention relates to pharmaceutical multilayer dosage forms, for example to a tamper resistant dosage form comprising a first layer comprising an active agent and a second layer not comprising said active agent, and processes of manufacture, uses, and methods of treatment thereof providing essentially zero order release.
PCT/IB2012/000595 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms WO2012131463A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
ES12717468.8T ES2544735T3 (en) 2011-03-25 2012-03-22 Pharmaceutical controlled release dosage forms
EP20120717468 EP2688556B1 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
BR112013024585A BR112013024585A8 (en) 2011-03-25 2012-03-22 controlled release pharmaceutical dosage forms
DK12717468.8T DK2688556T3 (en) 2011-03-25 2012-03-22 Pharmaceutical dosage forms with controlled release
JP2014500486A JP5964940B2 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage form
KR1020137027839A KR101619579B1 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
CN201280020303.9A CN103547259A (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
AU2012235878A AU2012235878B2 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
CA2831218A CA2831218C (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
RS20150515A RS54152B1 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
PL12717468T PL2688556T3 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
US14/004,857 US20140056979A1 (en) 2011-03-25 2012-03-22 Controlled Release Pharmaceutical Dosage Forms
NZ616600A NZ616600B2 (en) 2011-03-25 2012-03-22 Tamper-resistant controlled release pharmaceutical dosage forms
MEP-2015-116A ME02189B (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
MX2013010987A MX350875B (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms.
SI201230275T SI2688556T1 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms
IL228441A IL228441B (en) 2011-03-25 2013-09-15 Controlled release pharmaceutical dosage forms
ZA2013/07862A ZA201307862B (en) 2011-03-25 2013-10-22 Controlled release pharmaceutical dosage forms
HRP20150835TT HRP20150835T1 (en) 2011-03-25 2015-08-04 Controlled release pharmaceutical dosage forms
SM201500209T SMT201500209B (en) 2011-03-25 2015-09-09 Pharmaceutical controlled release dosage forms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161467824P 2011-03-25 2011-03-25
US61/467,824 2011-03-25

Publications (2)

Publication Number Publication Date
WO2012131463A2 WO2012131463A2 (en) 2012-10-04
WO2012131463A3 true WO2012131463A3 (en) 2012-11-29

Family

ID=46018006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2012/000595 WO2012131463A2 (en) 2011-03-25 2012-03-22 Controlled release pharmaceutical dosage forms

Country Status (23)

Country Link
US (1) US20140056979A1 (en)
EP (1) EP2688556B1 (en)
JP (1) JP5964940B2 (en)
KR (1) KR101619579B1 (en)
CN (1) CN103547259A (en)
AU (1) AU2012235878B2 (en)
BR (1) BR112013024585A8 (en)
CA (1) CA2831218C (en)
CY (1) CY1116579T1 (en)
DK (1) DK2688556T3 (en)
ES (1) ES2544735T3 (en)
HR (1) HRP20150835T1 (en)
HU (1) HUE026981T2 (en)
IL (1) IL228441B (en)
ME (1) ME02189B (en)
MX (1) MX350875B (en)
PL (1) PL2688556T3 (en)
PT (1) PT2688556E (en)
RS (1) RS54152B1 (en)
SI (1) SI2688556T1 (en)
SM (1) SMT201500209B (en)
WO (1) WO2012131463A2 (en)
ZA (1) ZA201307862B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
NZ529928A (en) 1999-10-29 2005-10-28 Euro Celtique Sa Controlled release hydrocodone formulations
KR101045144B1 (en) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 Controlled release hydrocodone formulations
EP1429739A1 (en) 2001-09-21 2004-06-23 Egalet A/S Polymer release system
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2301526B1 (en) 2003-03-26 2016-03-23 Egalet Ltd. Morphine controlled release system
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ603579A (en) 2009-06-24 2014-02-28 Egalet Ltd Controlled release formulations
CN103370058A (en) 2010-12-22 2013-10-23 普渡制药公司 Encased tamper resistant controlled release dosage forms
CN107412173A (en) 2010-12-23 2017-12-01 普渡制药公司 Anti-distort solid oral dosage form
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EA201590165A1 (en) 2012-07-06 2015-08-31 Эгалет Лтд. CONTAINING ABUSE OF PHARMACEUTICAL COMPOSITIONS FOR CONTROLLED LIBERATION
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US9839212B2 (en) 2015-04-16 2017-12-12 Bio-Lab, Inc. Multicomponent and multilayer compacted tablets
JP7335870B2 (en) * 2017-08-31 2023-08-30 パーデュー、ファーマ、リミテッド、パートナーシップ Pharmaceutical dosage form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036099A1 (en) * 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
WO2006002884A1 (en) * 2004-07-01 2006-01-12 Grünenthal GmbH Oral dosage form safeguarded against abuse
EP1897545A1 (en) * 2006-08-25 2008-03-12 Purdue Pharma LP Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950007907B1 (en) * 1992-09-01 1995-07-21 동국제약 주식회사 Pharmaceutical preparation for dental use
US5567439A (en) * 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
US5634702A (en) 1995-09-27 1997-06-03 Fistonich; Juraj Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure
ATE340563T1 (en) * 2000-02-04 2006-10-15 Depomed Inc SHELL AND CORE TYPE DOSAGE FORM WITH A RELEASE OF ACTIVE INGREDIENTS APPROACHING TO THE ZERO ORDER
US7434308B2 (en) * 2004-09-02 2008-10-14 International Business Machines Corporation Cooling of substrate using interposer channels
JP2008536928A (en) * 2005-04-19 2008-09-11 アルザ・コーポレーシヨン A combination of tramadol and a substance comprising gabapentin
KR20090018055A (en) * 2006-05-17 2009-02-19 산드빅 인터렉츄얼 프로퍼티 에이비 A top hammer rock-drilling tool, a drill rod and coupling sleeve
WO2009012122A1 (en) * 2007-07-13 2009-01-22 Marvell World Trade Ltd. Method for shallow trench isolation
AU2009223061B2 (en) * 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
CN101933907A (en) * 2009-06-30 2011-01-05 北京天衡药物研究院 Novel matrix sustained-release tablet and preparation method thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036099A1 (en) * 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
WO2006002884A1 (en) * 2004-07-01 2006-01-12 Grünenthal GmbH Oral dosage form safeguarded against abuse
EP1897545A1 (en) * 2006-08-25 2008-03-12 Purdue Pharma LP Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HARIHARAN M AND GUPTA V K: "A novel compression-coated tablet dosage form", no. YEARBOOK 2001, 1 January 2001 (2001-01-01), pages 14 - 19, XP002678748, ISSN: 1543-2521, Retrieved from the Internet <URL:http://www.pharmtech.com/pharmtech/data/articlestandard/pharmtech/512001/5072/article.pdf> *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9579389B2 (en) 2013-02-05 2017-02-28 Purdue Pharma L.P. Methods of preparing tamper resistant pharmaceutical formulations

Also Published As

Publication number Publication date
SMT201500209B (en) 2015-10-30
IL228441B (en) 2019-05-30
NZ616600A (en) 2015-07-31
US20140056979A1 (en) 2014-02-27
EP2688556B1 (en) 2015-05-06
PT2688556E (en) 2015-09-11
KR101619579B1 (en) 2016-05-10
SI2688556T1 (en) 2015-09-30
EP2688556A2 (en) 2014-01-29
BR112013024585A8 (en) 2018-01-09
AU2012235878B2 (en) 2015-10-15
DK2688556T3 (en) 2015-08-03
IL228441A0 (en) 2013-12-31
JP5964940B2 (en) 2016-08-03
MX350875B (en) 2017-09-19
RS54152B1 (en) 2015-12-31
PL2688556T3 (en) 2015-10-30
CY1116579T1 (en) 2017-03-15
HUE026981T2 (en) 2016-08-29
AU2012235878A1 (en) 2013-05-02
WO2012131463A2 (en) 2012-10-04
CA2831218C (en) 2017-01-17
CN103547259A (en) 2014-01-29
ES2544735T3 (en) 2015-09-03
KR20130135973A (en) 2013-12-11
HRP20150835T1 (en) 2015-09-11
MX2013010987A (en) 2014-10-13
JP2014510094A (en) 2014-04-24
ME02189B (en) 2016-02-20
CA2831218A1 (en) 2012-10-04
ZA201307862B (en) 2014-06-25

Similar Documents

Publication Publication Date Title
WO2012131463A3 (en) Controlled release pharmaceutical dosage forms
CL2013002504A1 (en) Solid coated pharmaceutical preparation comprising at least one active ingredient and because the coating has a thickness of 0.1 to 100 nm, preferably 0.3 to 50 nm and more preferably 0.5 to 35 nm; and its method of preparation
WO2014002051A3 (en) Complement pathway modulators and uses thereof
WO2014002058A3 (en) Complement pathway modulators and uses thereof
WO2012174158A3 (en) Administration of benzodiazepine
WO2014009833A3 (en) Complement pathway modulators and uses thereof
WO2011099832A3 (en) Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
EP2657231A4 (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
CL2014000849A1 (en) Compounds derived from substituted benzylindazoles, bub1 kinase inhibitors; manufacturing procedure; pharmaceutical composition; pharmaceutical combination; and its use in the treatment of hyperproliferative diseases.
EP2699584A4 (en) Cyclic peptide from nonomuraea sp., process for the production thereof, and pharmaceutical composition for the prevention or treatment of mycobacteria related disease comprising the same
MY176793A (en) Pharmaceutical tablet comprising acetylsalicylic acid and clopidogrel
WO2013003669A3 (en) Compositions, methods of use, and methods of treatment
WO2012162439A3 (en) Compositions comprising fusidic acid and packages therefor
WO2014078576A3 (en) Oral transmucosal drug delivery system
WO2012156023A8 (en) Process for producing inorganic particulate material
WO2012158030A3 (en) Drug delivery system
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
WO2012066132A3 (en) Multilayer ceramic structures
WO2011155728A3 (en) Composition for preventing or treating osteoporosis, and manufacturing method therefor
WO2014125504A3 (en) Pharmaceutical compositions of febuxostat
GEP201706614B (en) Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process
WO2011107921A3 (en) Modified release composition of milnacipran
WO2014013090A3 (en) Formulation comprising amorphous fingolimod
WO2014056779A8 (en) Drug for the prophylaxis and treatment of a neurodegenerative disease
WO2012141502A3 (en) Controlled release type tablet containing aceclofenac

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2012235878

Country of ref document: AU

Date of ref document: 20120322

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2014500486

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2831218

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2013/010987

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012717468

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20137027839

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14004857

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112013024585

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: P-2015/0515

Country of ref document: RS

ENP Entry into the national phase

Ref document number: 112013024585

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20130925